Pfizer Inc. (VIE:PFE)
Austria · Delayed Price · Currency is EUR | Market Cap | 152.52B +26.0% |
| Revenue (ttm) | 55.85B -0.2% |
| Net Income | 3.80B -59.7% |
| EPS | 0.68 -59.9% |
| Shares Out | n/a |
| PE Ratio | 39.00 |
| Forward PE | 10.30 |
| Dividend | 1.49 (5.61%) |
| Ex-Dividend Date | Nov 6, 2026 |
| Volume | 1,916 |
| Open | 26.62 |
| Previous Close | 26.30 |
| Day's Range | 26.62 - 27.00 |
| 52-Week Range | 20.60 - 27.08 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Looking for income? These dividend stocks have high yields that seem well supported.
Ford, Pfizer and Verizon are among 11 stocks that passed a screen of the S&P 500 for high dividend yields that are expected to be well covered by the companies' free cash flow.
Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development
SAN FRANCISCO--(BUSINESS WIRE)--Edison Scientific announces agreement with Pfizer to accelerate research and development.
ManpowerGroup appoints Lidia Fonseca to board of directors
ManpowerGroup (MAN) announced the election of Lidia Fonseca, former Executive Vice President and Chief Digital and Technology Officer at Pfizer (PFE), to its Board of Directors, effective November 1. ...
Pfizer says Phase 3 MagnetisMM-32 study met primary endpoint
Pfizer (PFE) announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO as monotherapy in adults with relapsed or refractory multiple myeloma who received at least one prior li...
Pfizer's ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or ref...
Pfizer announces FDA expanded approval for TALZENNA plus XTANDI
Pfizer (PFE) announced that the U.S. Food and Drug Administration has expanded approval of TALZENNA in combination with XTANDI to the treatment of men with metastatic androgen pathway modulation-naive...
Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalu...
FDA announces approval of Pfizer’s Talzenna combination for prostate cancer
The Food and Drug Administration said it approved Pfizer’s (PFE) Talzenna in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation-naive or -sensitive p...
Pfizer announces results across serotypes in Phase 2 study of 25vPnC
Pfizer (PFE) announced detailed results across serotypes from a Phase 2 study for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412, 25vPnC, in infants. In the study,...
Pfizer (PFE) Lung Cancer Drug Shows Survival Benefit Despite Trial Failure
Pfizer ($PFE) is keeping its experimental lung cancer drug alive despite a failed clinical trial. New data showed that some patients treated with sigvotatug vedotin lived more than two months…
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine...
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipe...
Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry
Regulators allege the ex-drug executive held more than 60 pharmaceutical stocks despite a court order barring him from the industry.
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules
PARIS--(BUSINESS WIRE)-- #Biotech--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it...
Pfizer price target raised to $30 from $28 at JPMorgan
JPMorgan raised the firm’s price target on Pfizer (PFE) to $30 from $28 and keeps a Neutral rating on the shares.
Pfizer price target raised to $29 from $27 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Pfizer (PFE) to $29 from $27 and keeps a Neutral rating on the shares as part of the firm’s Q3…
The AI Change That Let Pfizer's Albert Bourla Sleep Better
Albert Bourla found himself thinking about it a lot: Why wasn't the company seeing better results from AI? “I spent all my nights before sleep thinking what I did right and what I did wrong, and that ...
Pfizer price target raised to $28 from $27 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Pfizer (PFE) to $28 from $27 and keeps a Neutral rating on the shares. MEVPRO-1 has largely defined the near-term setup, leaving…
Pfizer to cut 300 jobs in Italy, confirms closure of penicillins department
In a statement, CISL, a national trade union in Italy, said, “The meeting held yesterday afternoon at the Ministry of Enterprise and Made in Italy on the dispute at the…
Pfizer announces FDA approval of TUKYSA regimen for HER2+ breast cancer
Pfizer (PFE) announced that the U.S. Food and Drug Administration has approved TUKYSA in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally a...
Pfizer's TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for ...
Pfizer to cut around 330 jobs in Italy
Pfizer will cut around 330 jobs in Italy at its Sicily plant, labour unions said on Wednesday, making the US drugmaker the latest international company downsizing its Italian operations.
Pfizer price target raised to $33 from $30 at Scotiabank
Scotiabank raised the firm’s price target on Pfizer (PFE) to $33 from $30 and keeps an Outperform rating on the shares. The firm believes the increase is warranted due to…
Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer – – VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gast...